doi:10.1055/s-0036-1594292 Belcaro G, Cesarone MR, Scipione C, et al
The mechanism behind lipid improvement extends beyond simple weight loss
We assessed the effects of the drugs on the physiological status of diabetic mice by measuring blood glucose, body weight, and cell counts in several organs, as well as effects of thymulin and PRDX6 on the immune status of diabetic mice measuring concentrations of pro-inflammatory cytokines in blood plasma (TNF-, interleukin-5 and 17, and interferon-), activity of NF-B and JNK pathways, and Hsp90 expression in immune cells
DATA GRAPHICS | Product Development Retatrutide data strengthen Lillys hand in high-BMI obesity Phase III data put weight loss above CagriSemas benchmark, with tolerability that may be good enough to preserve a commercial edge May 21, 2026 7:09 PM UTC Lilly again has the frontrunner in the weight loss Olympics: its triple agonist retatrutide showed greater Phase III obesity efficacy than Novo Nordisks dual-acting CagriSema, with a tolerability profile that does not appear markedly worse
Specifically, semaglutide at 30 nmol/kg has been widely employed to achieve sustained weight loss and glycemic improvement (18, 21), while tirzepatide at 10 nmol/kg has been validated to produce comparable or greater metabolic benefits due to its higher potency and dual GIP/GLP-1 receptor agonism (17, 20)
E, EMC3-tag
